Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on 11C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-03-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/514191 |
id |
doaj-aebbadc68d6a4a068fb4b522fd4f4cf8 |
---|---|
record_format |
Article |
spelling |
doaj-aebbadc68d6a4a068fb4b522fd4f4cf82021-04-15T14:58:48ZengKarger PublishersCase Reports in Oncology1662-65752021-03-0114152052410.1159/000514191514191Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CTKazuhiro Kitajima0Shingo Yamamoto1Masayuki Fujiwara2Yusuke Kawanaka3Yusuke Yamada4Seiji Nagasawa5Kimihiro Shimatani6Takeshi Hanasaki7Motohiro Taguchi8Akihiro Kanematsu9Koichiro Yamakado10Department of Radiology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Radiology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Radiology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Urology, Hyogo College of Medicine, Nishinomiya, JapanDepartment of Radiology, Hyogo College of Medicine, Nishinomiya, JapanWe here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on 11C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal 11C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal 11C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal 11C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. 11C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC.https://www.karger.com/Article/FullText/514191castration-resistant prostate cancercholine pet/ctbone metastasistreatment response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kazuhiro Kitajima Shingo Yamamoto Masayuki Fujiwara Yusuke Kawanaka Yusuke Yamada Seiji Nagasawa Kimihiro Shimatani Takeshi Hanasaki Motohiro Taguchi Akihiro Kanematsu Koichiro Yamakado |
spellingShingle |
Kazuhiro Kitajima Shingo Yamamoto Masayuki Fujiwara Yusuke Kawanaka Yusuke Yamada Seiji Nagasawa Kimihiro Shimatani Takeshi Hanasaki Motohiro Taguchi Akihiro Kanematsu Koichiro Yamakado Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT Case Reports in Oncology castration-resistant prostate cancer choline pet/ct bone metastasis treatment response |
author_facet |
Kazuhiro Kitajima Shingo Yamamoto Masayuki Fujiwara Yusuke Kawanaka Yusuke Yamada Seiji Nagasawa Kimihiro Shimatani Takeshi Hanasaki Motohiro Taguchi Akihiro Kanematsu Koichiro Yamakado |
author_sort |
Kazuhiro Kitajima |
title |
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_short |
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_full |
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_fullStr |
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_full_unstemmed |
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT |
title_sort |
accurate monitoring of the response of bone metastases to treatment in patients with prostate cancer using choline pet/ct |
publisher |
Karger Publishers |
series |
Case Reports in Oncology |
issn |
1662-6575 |
publishDate |
2021-03-01 |
description |
We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on 11C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal 11C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal 11C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal 11C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. 11C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC. |
topic |
castration-resistant prostate cancer choline pet/ct bone metastasis treatment response |
url |
https://www.karger.com/Article/FullText/514191 |
work_keys_str_mv |
AT kazuhirokitajima accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT shingoyamamoto accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT masayukifujiwara accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT yusukekawanaka accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT yusukeyamada accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT seijinagasawa accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT kimihiroshimatani accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT takeshihanasaki accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT motohirotaguchi accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT akihirokanematsu accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct AT koichiroyamakado accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct |
_version_ |
1721526226953175040 |